HIV TREATMENT
2020
Action 27. Mobilize their networks and work with communities to help build treatment literacy, generate demand, and expand access to ARVs among children.
Action 34. Increase efforts to share information on the roll-out of new paediatric formulations, including lessons learned.
Paediatric HIV & TB : Rome Action Plan
Prioritize PADO products in research and development plans
Pharmaceutical companies
Prioritize PADO products in research and development plans
Pharmaceutical companies
ViiV has committed additional resources in Pediatrics with the appointment of a Head of Pediatric Strategy (Bill Collier) who has convened a cross-functional team to address possible ways to accelerate development of DTG for pediatrics.
-
Review ARV portfolio, prioritize PADO products and communicate changes with stakeholders by IAC July 2018.
-
-
-
Demonstrate timely implementation of PADO priorities as part of their paediatric portfolio (by 2020).
-
-
-
-
-
-
-
Sub-Actions & Milestones
Updates
Notes
Responsible